News Column

Dr. John Monahan, a Veteran in Biotechnology and Gene Therapy Companies, Joins the Scientific Advisory Board of Agilis Biotherapeutics

June 18, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Agilis Biotherapeutics, LLC, a synthetic biology-based company focused on developing best-in-class DNA-based therapeutics for rare genetic diseases, announced that John Monahan, Ph.D., a veteran CEO of biotechnology and gene therapy companies, has joined its Scientific Advisory Board (see also Agilis Biotherapeutics, LLC).

Dr. Monahan founded and built Avigen Inc., a company which became a leader in its sector for the development of pharmaceutical products for the treatment of serious human disease. He led the company through a number of investigational new drug applications and helped Avigen raise more than $200 million, including through its initial public offering. Dr. Monahan has directed numerous biotech and pharmaceutical research, preclinical and clinical programs and has extensive knowledge of the basic sciences and has held various positions in industry and academia. Currently, he is Executive Vice President Research & Development for Synthetic Biologics. He also serves on the boards of several biotechnology companies. He holds a Ph.D. in Biochemistry from McMaster University, Canada, and a B.Sc. from University College Dublin, Ireland.

"We are delighted to welcome Dr. Monahan as a scientific advisor to the Company," said G. Houston Hall, Chairman of Agilis. "Dr. Monahan brings deep experience and expertise to Agilis to guide our strategic initiatives."

"I am thrilled to be joining such an innovative and forward-looking company," said Dr. Monahan. "I look forward to helping Agilis grow in this extremely exciting time for the company and for gene therapy." About Agilis Biotherapeutics, LLC Agilis Biotherapeutics, LLC, is a biotechnology company focused on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are limited or no treatment options. We believe that engineered DNA-based therapeutics provide the ability to target underlying disease mechanisms with tightly-controlled multigenic modalities leading to "functional cures" for patients with these diseases.

Keywords for this news article include: Biotechnology, Agilis Biotherapeutics LLC.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters